RUBY - Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Shitanshu Uppal
NRG GY018: Pembrolizumab in Advanced Endometrial Cancer
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
MITO-7: Weekly chemotherapy in ovarian cancer
Weekly chemotherapy vs. q3 weekly chemotherapy in advanced ovarian cancer
BEATcc: Atezolizumab added to Cis/Taxol/Bev in recurrent/metastatic cervical cancer
Atezolizumab plus bevacizumab and chemotherapy for
metastatic, persistent, or recurrent cervical cancer (BEATcc)
Publications Update # 42
New Year Resolutions, BEATcc trial exploring PD-L1 inhibitors in cervical cancer, chemotherapy regimens for older patients with ovarian cancer, and NRG-GY012 published.
Publications Update # 41
Happy Holidays and Happy New Year
GOG 281: Trametinib in recurrent low-grade serous ovarian cancer
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer.
MIRASOL: Mirvetuximab in Platinum Resistant Cancer
Mirvetuximab Soravtansine (MIRV) in platinum resistant ovarian cancer
RHIP Framework for Change Management
RHIP framework can help with change management
EORTC-55994 and Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
EORTC and the trial from TATA memorial. Is neoadjuvant chemotherapy and surgery an alternative to chemoradiation in locally advanced cervical cancer?